STAGE III RENAL CELL CANCER AJCC V8

This study tests a combination of three drugs (ixazomib, gemcitabine, and doxorubicin) in 30 people with a rare and aggressive kidney cancer that has spread. The goal is to see if the treatment can shrink tumors or stop them from growing. Participants receive the drugs in cycles,…

This study compares two treatment options for people with advanced kidney cancer that has spread and worsened after prior immunotherapy. About 90 participants will receive either a combination of two drugs (lenvatinib and everolimus) or a single drug (cabozantinib). The goal is t…

This early-phase trial tests adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) for people with advanced kidney cancer that has spread. The main goal is to find the safest dose and see how it affects gut bacteria. About 31 participants will …

This early-phase study tests whether adding a gut bacteria supplement (CBM588) to standard cancer drugs (nivolumab and cabozantinib) can improve treatment for advanced kidney cancer. About 31 adults with metastatic kidney cancer will take the supplement alongside their regular th…

This study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with locally advanced kidney cancer that hasn't spread to other parts of the body. About 18 participants will receive the combination for 12 weeks before their operat…

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

This study tests whether combining two drugs—axitinib (which blocks cancer cell growth) and nivolumab (which helps the immune system attack cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes …

This study tests a drug called adavosertib in people with advanced solid tumors that lack a working SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. The trial includes 18 adults whose cancer has spread and who have already tried other treatments. The…

This early-stage trial was designed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. The treatment uses a patient's own immune cells (T cells) taken fro…